Harrow (HROW) Expected to Announce Earnings on Monday

Harrow (NASDAQ:HROW) is expected to announce its Q3 2025 results after the market closes on Monday, November 10th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $73.6960 million for the quarter. Harrow has set its Q2 2023 guidance at EPS.Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 11, 2025 at 8:00 AM ET.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Tuesday, July 18th. The company reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $22.12 million during the quarter. Harrow had a negative net margin of 4.49% and a negative return on equity of 2.18%. On average, analysts expect Harrow to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Harrow Price Performance

NASDAQ HROW opened at $37.09 on Monday. The company has a market cap of $1.37 billion, a P/E ratio of -147.66 and a beta of 0.27. Harrow has a 1 year low of $20.85 and a 1 year high of $54.19. The company has a fifty day simple moving average of $41.10 and a 200 day simple moving average of $34.28. The company has a current ratio of 0.62, a quick ratio of 0.58 and a debt-to-equity ratio of 0.78.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE raised its holdings in Harrow by 266.8% in the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock worth $6,519,000 after purchasing an additional 155,258 shares during the period. Invesco Ltd. raised its holdings in Harrow by 967.6% in the second quarter. Invesco Ltd. now owns 150,948 shares of the company’s stock worth $4,610,000 after purchasing an additional 136,809 shares during the period. First Trust Advisors LP bought a new position in Harrow in the second quarter valued at approximately $2,539,000. Engineers Gate Manager LP lifted its stake in Harrow by 194.7% in the second quarter. Engineers Gate Manager LP now owns 35,565 shares of the company’s stock valued at $1,086,000 after buying an additional 23,495 shares in the last quarter. Finally, Quantbot Technologies LP bought a new position in Harrow in the second quarter valued at approximately $274,000. Institutional investors own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on HROW. BTIG Research reiterated a “buy” rating and set a $63.00 target price on shares of Harrow in a research note on Wednesday, September 24th. HC Wainwright restated a “buy” rating and issued a $64.00 price objective on shares of Harrow in a research report on Monday, September 29th. B. Riley restated a “buy” rating and issued a $74.00 price objective (up previously from $70.00) on shares of Harrow in a research report on Wednesday, October 1st. Cantor Fitzgerald initiated coverage on shares of Harrow in a research report on Friday, July 11th. They issued an “overweight” rating and a $76.00 price objective for the company. Finally, Zacks Research cut shares of Harrow from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 12th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $68.50.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.